FIELD: biotechnology; medicine.
SUBSTANCE: present invention refers to new antibodies and their fragments capable of binding to cannabinoid receptor 1 (CB1). Antibodies and fragments described herein include humanised antibodies capable of binding to the CB1 receptor. Present invention also relates to use of said antibodies for treating a disease or disorder, responding to the CB1 receptor antagonist or agonist effect.
EFFECT: there are presented antibodies able to bind to human cannabinoid receptor 1 (CB1).
12 cl, 31 dwg, 39 tbl, 32 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES BINDING TO HUMAN CANNABINOID RECEPTOR 1 (CB1) | 2015 |
|
RU2730674C2 |
| HUMANIZED ANTI-SIRPα ANTIBODIES | 2019 |
|
RU2812199C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING AND VEGF ANTAGONISTS | 2013 |
|
RU2689760C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| ANTIBODIES AGAINST XI CLOTTING FACTOR | 2017 |
|
RU2757314C2 |
| ANTIBODIES AGAINST TNFRSF9 AND THEIR USE | 2019 |
|
RU2812200C2 |
| COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES | 2010 |
|
RU2569109C2 |
| HUMANISED ANTIBODIES AGAINST HUMAN ALPHA INTERFERON | 2009 |
|
RU2532832C2 |
| ANTIBODIES TO PD-1 AND COMPOSITIONS | 2016 |
|
RU2750675C1 |
